AGC Biologics expands dual-site pharmaceutical manufacturing contract to more than €500 million

AGC Biologics has expanded a long-term manufacturing agreement with an unnamed global pharmaceutical company to more than €500 million, adding six commercial biologics programmes at its Copenhagen facility.

The agreement announced on 3 November 2026 extends an existing five-programme manufacturing relationship at AGC Biologics' Yokohama site in Japan to Copenhagen, Denmark, creating an 11-programme dual-site arrangement encompassing technology transfer, scale-up, validation and commercial drug-substance manufacturing.

The expanded contract exceeds €500 million in total value and includes planned regulatory submissions for the two manufacturing locations, although neither the customer's identity nor the incremental financial value of the newly added Copenhagen work was disclosed.

Field	Content
Article Type	Deals
Company	AGC Biologics
Customer	Undisclosed global pharmaceutical company
Deal Type	Expanded long-term commercial biologics manufacturing agreement
Announcement Date	3 November 2026
Transaction Status	Contract expansion announced
Total Expanded Contract Value	More than €500 million
Incremental Contract Value	Not disclosed
Financial Clarification	The €500 million-plus figure represents total expanded contract value, not necessarily incremental new business.
Existing Manufacturing Programmes	Five programmes
Additional Manufacturing Programmes	Six programmes
Combined Programme Count	11 programmes
Existing Manufacturing Site	Yokohama, Japan
Additional Manufacturing Site	Copenhagen, Denmark
Manufacturing Arrangement	Dual-site commercial biologics manufacturing
Product Category	Biologics
Manufacturing Activities	Technology transfer; process scale-up; validation; commercial drug-substance manufacturing
Regulatory Activities	Planned dual-site regulatory submissions
Manufacturing Stage	Commercial manufacturing
Customer Identity	Not disclosed
Therapeutic Indications	Not disclosed
Geographic Scope	Denmark and Japan
What Happened	AGC Biologics expanded an existing manufacturing agreement to include six additional commercial biologics programmes at its Copenhagen facility.
Why It Matters	The agreement demonstrates substantial demand for commercial biologics manufacturing capacity and extends an established customer relationship across two international production sites.
Strategic Rationale	Expand manufacturing capacity, support supply continuity and provide geographically diversified commercial production capabilities.
Operational Significance	The arrangement connects existing Yokohama manufacturing activities with additional Copenhagen programmes and planned regulatory submissions.
Key Takeaway	AGC Biologics' expanded contract exceeds €500 million in total value, while the incremental value of the expansion remains undisclosed.
What to Watch	Technology transfer progress, manufacturing validation, regulatory submissions, production ramp-up and future programme additions.
Primary Source	AGC Biologics
Primary Source URL	https://www.agcbio.com/news/global-pharmaceutical-company-commits-to-a-dual-site-deal-with-agc-biologics-exceeding-0.5-billion
Relevant Date	3 November 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com